Court grants preliminary approval to Ginkgo Bioworks derivative settlement; $4.125M from insurance

Ginkgo Bioworks Holdings, Inc.

Company receives $4.125M from insurance; plaintiffs' counsel may request $2.75M in fees.
Settlement requires Ginkgo to adopt corporate governance reforms.
Derivative actions (Hu, Bowers, In re Ginkgo) will be dismissed with prejudice.
Final hearing set for December 18, 2025; settlement entered on May 27, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.